Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome
Top Cited Papers
- 1 August 2002
- journal article
- clinical trial
- Published by American Society of Hematology in Blood
- Vol. 100 (13) , 4337-4343
- https://doi.org/10.1182/blood-2002-04-1216
Abstract
Veno-occlusive disease (VOD) is the most common regimen-related toxicity accompanying stem cell transplantation (SCT). Severe VOD complicated by multisystem organ failure (MOF) remains almost uniformly fatal. Preliminary experience with defibrotide (DF), a single-stranded polydeoxyribonucleotide with fibrinolytic, antithrombotic, and anti-ischemic properties, in the treatment for severe VOD has suggested safety and activity. Eighty-eight patients who developed severe VOD after SCT were treated with DF under a defined treatment plan. At diagnosis, median bilirubin was 76.95 μM (4.5 mg/dL), median weight gain was 7%, ascites was present in 84%, and abnormal hepatic portal venous flow was present in 35%. At DF initiation, median bilirubin had increased to 215.46 μM (12.6 mg/dL), and MOF was present in 97%. DF was administered intravenously in doses ranging from 5 to 60 mg/kg per day for a median of 15 days. No severe hemorrhage or other serious toxicity related to DF was reported. Complete resolution of VOD was seen in 36%, with 35% survival at day +100. Predictors of survival included younger age, autologous SCT, and abnormal portal flow, whereas busulfan-based conditioning and encephalopathy predicted worse outcome. Decreases in mean creatinine and plasminogen activator inhibitor 1(PAI-1) levels during DF therapy predicted better survival. The complete response rate, survival to day +100, and absence of significant DF-associated toxicity in this largest patient cohort reported to date confirm the results of earlier studies. Certain features associated with successful outcome may correlate with DF-related treatment effects, and prospective evaluation of DF therapy for severe VOD should allow better definition of predictors of response or failure.Keywords
This publication has 29 references indexed in Scilit:
- Toxic Injury to Hepatic Sinusoids: Sinusoidal Obstruction Syndrome (Veno-Occlusive Disease)Seminars in Liver Disease, 2002
- Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use studyBritish Journal of Haematology, 2000
- N-acetylcysteine for hepatic veno-occlusive disease after allogeneic stem cell transplantationBone Marrow Transplantation, 2000
- Autologous bone marrow transplantation in non-Hodgkin’s lymphoma patients: effect of a brief course of G-CSF on harvest and recoveryBone Marrow Transplantation, 1999
- Defibrotide as salvage therapy for refractory veno-occlusive disease of the liver complicating allogeneic bone marrow transplantationBone Marrow Transplantation, 1999
- Hepatic stellate cells (Ito cells) in veno-occlusive disease of the liver after allogeneic bone marrow transplantationHistopathology, 1999
- Venoocclusive disease of the liver after marrow transplantation: Histological correlates of clinical signs and symptomsHepatology, 1994
- DefibrotideCardiovascular Drug Reviews, 1991
- A LIGHT AND SCANNING ELECTRON MICROSCOPIC STUDY OF HEPATIC VENO‐OCCLUSIVE DISEASEActa Pathologica Japonica, 1987
- Effect of a New Antithrombotic Agent (Defibrotide) in Acute Renal Failure Due to Thrombotic MicroangiopathyNephron, 1985